AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

MINNEAPOLIS and TEL AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, and Nucleai, a leader in AI-powered multimodal spatial biology for precision medicine, today announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.  

Read more at prnewswire.com